3D Scaffold Rare Cell Capture for High-Volume Blood Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CTC trapping technologies struggle with low abundance, heterogeneity, and dynamic changes in circulating tumor cells, leading to inefficiencies in detection and processing large blood volumes, and often require invasive methods or costly antibodies.
Innovation Solution
A 3D scaffold system that is chemically functionalized to bind specific cell surface markers, allowing high-throughput trapping and amplification of CTCs without exogenous agents, with a closed-loop system for multiple passes through the scaffold.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If magnetic nanoparticle-based technologies are used for CTC trapping, then CTC enrichment efficiency is improved, but the need for injection of nanoparticles and complex processing procedures increases
Solution Approach 1:
The patent extracts and removes the need for exogenous magnetic nanoparticles from the system. Instead of injecting nanoparticles into the patient, the invention uses a nanoparticle-free microfluidic device that relies on inherent physical and chemical properties of CTCs (size, deformability, surface markers) for separation, thereby eliminating the complexity of nanoparticle injection and handling
Solution Approach 2:
The patent introduces a microfluidic chip with specific structural features (sinusoidal channels, herringbone patterns, immunocapture antibodies) as an intermediary mechanism. This mediator enables CTC separation through controlled fluid dynamics and selective binding, replacing the need for magnetic nanoparticles while maintaining enrichment efficiency
2Measurement precision
If microfluidic separation technologies are used for CTC trapping, then CTC isolation capability is improved, but processing time increases and throughput remains limited
Solution Approach 1:
The patent transitions from traditional two-dimensional planar channels to a three-dimensional microfluidic architecture with sinusoidal and herringbone patterns. This dimensional complexity creates multiple flow paths and enhancement regions within a compact footprint, increasing the effective processing capacity and throughput while maintaining precise CTC isolation
Solution Approach 2:
The microfluidic chip is segmented into multiple functional zones including sinusoidal channels for initial separation, herringbone patterns for enhancement, and immunocapture regions for final isolation. This segmentation allows parallel processing of different cell populations and increases overall throughput while maintaining isolation capability
3Measurement precision
If EpCAM targeted magnetic nanoparticles are used for CTC trapping, then CTC binding efficiency is improved, but EpCAM-negative CTCs and small CTCs are missed
Solution Approach 1:
The patent employs multiple targeting strategies simultaneously within the same microfluidic device: size-based filtration, deformability-based separation, and immunocapture with multiple antibody targets (including EpCAM and non-EpCAM markers). This multi-functional approach ensures universal capture of diverse CTC subtypes including small CTCs and EpCAM-negative cells that would be missed by EpCAM-specific nanoparticles alone
4Measurement precision
If large volumes of blood are processed for CTC detection, then CTC detection sensitivity is improved, but processing time and patient burden increase
Solution Approach 1:
The patent performs preliminary enrichment and concentration of CTCs within the microfluidic chip before final analysis. The sinusoidal and herringbone patterns pre-separate CTCs from the bulk blood stream, and immunocapture antibodies pre-bind to CTC surfaces, reducing the volume that requires detailed analysis and thereby decreasing overall processing time while maintaining detection sensitivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables efficient trapping of rare cells from large blood volumes with minimal background interference, maintaining cell viability for downstream analysis, and reducing processing time and invasiveness.
Implementation Method 1
a 3D scaffold disposed within the inner volume and chemically functionalized to bind circulating tumor cells, extracellular vesicles, or combinations thereof, in the fluid stream
Data Source
AI summary
A system for collecting biomarkers from a fluid stream includes a collection vessel having at least one fluid port that is adapted to be in fluid communication with the fluid stream. The collection vessel defines an inner volume. A 3D scaffold is disposed within the inner volume of the collection vessel. The 3D scaffold is chemically functionalized to bind the biomarkers in the fluid stream, wherein the biomarkers are eukaryotic cells of interest, extracellular vesicles associated with the eukaryotic cells of interest, or combinations thereof. A fluid driver circulates the fluid stream through the collection vessel via the at least one fluid port such that the fluid stream interacts with the 3D scaffold.